236
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

Stability Indicating RP-HPLC Studies for the Estimation of Irbesartan and Amlodipine Besylate in Pharmaceutical Formulations and Identification and Characterization of Degradants Using LC-MS

, , &
 

Abstract

A simple, specific, accurate, and stability-indicating reversed-phase high-performance liquid chromatography method was developed for simultaneous estimation of irbesartan and amlodipine besylate in pharmaceutical formulations. The chromatographic separation was achieved on a Zorbax CN column using a mixture of 1 mM potassium dihydrogen phosphate (pH 3.0) and acetonitrile (70:30, v/v) as the mobile phase at a flow rate of 0.9 mL/min. Detection was carried out at 240 nm. The calibration curves were linear (R 2 ≥ 0.99) over a concentration range of 6–42 µg/mL for irbesartan and 2–14 µg/mL for amlodipine besylate. The retention times of irbesartan and amlodipine besylate were 9.6 and 7.6 min, respectively. For stability studies, irbesartan and amlodipine besylate stock solutions were subjected to acid, alkali hydrolysis, chemical oxidation, and dry heat degradation. The degraded product peaks were well resolved from the pure drug peak with significant difference in their retention times and resolution. To elucidate structures of degradation products, the LC-MS method was used. The proposed method was successfully validated in accordance to the ICH guidelines acceptance criteria.

Notes

Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/ljlc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.